Haleon PLC, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Hayes from Jefferies maintained a Buy rating on the stock and has a p450.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Hayes has given his Buy rating due to a combination of factors including Haleon’s structural growth potential and current valuation. He expects like-for-like sales to grow more slowly this quarter than the long‑term 4%+ opportunity, mainly because of subdued demand in cold and flu products and continued softness in Latin American and European markets.
He argues that recent weakness in Germany and Brazil underlines the importance of delivering on broader emerging‑market growth initiatives, but also notes that management actions are already being implemented to capture this upside. With cold and flu trends starting to improve and the stock trading at about 17.5x next‑twelve‑month earnings, Hayes believes the risk‑reward profile is attractive enough to justify maintaining a Buy recommendation.
Hayes covers the Consumer Defensive sector, focusing on stocks such as DANONE SA, Nestlé SA, and Unilever. According to TipRanks, Hayes has an average return of 2.4% and a 54.75% success rate on recommended stocks.